tbuckley/cabot-search huggingface dataset:
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
Authors: S. J. Schuster, S. S. Neelapu, B. L. Gause, F. M. Muggia, J. P. Gockerman, E. M. Sotomayor, J. N. Winter, C. R. Flowers, A. M. Stergiou, L. W. Kwak
Journal: Journal of Clinical Oncology (2009)

2 Background: In previous trials, tumor-specific purified idiotype (Id) protein conjugated to keyhole limpet hemocyanin (KLH) administered with granulocyte-monocyte colony-stimulating factor (GM-CSF) induced follicular lymphoma (FL)-specific immune responses and molecular remissions (Nat Med. 1999;5:1171–7). Methods: We conducted a prospective randomized double-blind placebo-controlled multicenter phase III study of patient-specific autologous tumor-derived Id vaccine in advanced stage previously untreated FL patients (pts) with a lymph node adequate for vaccine production (≥ 2cm). Pts achieving complete response (CR) or complete response unconfirmed (CRu) after chemotherapy (PACE: prednisone, doxorubicin, cyclophosphamide, etoposide) were stratified by International Prognostic Index risk group and randomized 2:1 to receive either vaccination with Id-KLH/GM-CSF or control (KLH/GM-CSF). The primary endpoint was disease free survival. Results: 234 pts were enrolled; 177 (76%) achieved CR/CRu and were randomized. Of 177 randomized pts, 117 maintained CR/CRu ≥ 6 mo per protocol requirement and then received at least one dose of vaccine, 55 relapsed before vaccination, 4 were vaccine manufacturing failures, and 1 violated protocol. Pts who received ≥ one vaccine dose constituted the modified intent-to-treat population for determination of efficacy. 76 pts received Id-KLH/GM-CSF and 41 pts received the control (KHL/GM-CSF). No serious adverse events were attributed to Id vaccination. At a median follow-up of 56.6 mo (range 12.6 –89.3 mo), median time to relapse after randomization for the Id-KLH/GM-CSF arm was 44.2 mo, versus 30.6 mo for the control arm (p = 0.045; HR = 1.6). Conclusions: Id vaccination after a chemotherapy-induced remission of ≥ 6 mo prolongs remission duration in pts with FL. Compared to other phase III Id vaccine trials, the positive outcome of this study may reflect application of Id vaccine in pts in CR/CRu or use of hybridomas to produce Id. Genomic and immune response analyses are planned on residual autologous tumor and blood samples. Additional studies of this patient-specific vaccine in FL pts pretreated with anti-CD20 antibody-containing chemotherapy are indicated. [Table: see text]
Pulmonary osteoarthropathy. Association with mesenchymal tumor metastases to the lungs
Authors: J. J. Lokich
Journal: JAMA (1977)

Six of 18 patients with sarcomatous tumors metastatic to the lung had hypertrophic pulmonary osteoarthropathy (HPO), and, in three patients in whom tumor regression was achieved by cytotoxic chemotherapy or surgery, the clinical and radiologic changes of HPO were reversed. All six patients had large mass lesions (greater than 5 cm) that impinged on the pleural surface, and the pathophysiologic mechanism resulting in the clinical syndrome of HPO may be related to the anatomic relationship of the tumor and the pleura. The use of radionuclide scanning to detect HPO in the absence of roentgenographic signs or clinical symptoms is discussed. (<i>JAMA</i>238:37-39, 1977)
Effects of toxic chemicals on the reproductive system. Council on Scientific Affairs
Journal: JAMA (1985)

In an effort to make physicians more aware of the hazards of the workplace to pregnant workers, the Council on Scientific Affairs' Advisory Panel on Reproductive Hazards in the Workplace prepared this third and final report reviewing the effects of chemical exposure. A total of 120 chemicals were considered for reviews based on an estimation of their imminent hazard, ie, widespread use and/or inherent toxicity. Following a brief introduction, which sets out general principles, clinical applications, and aids to the recognition of a human teratogen, the report presents reviews and opinions for three representative chemicals. Information concerning the remaining 117 compounds is available upon request.
A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial
Authors: S. K. Williamson, J. Moon, C. H. Huang, P. Guaglianone, G. T. Wolf, S. G. Urba
Journal: Journal of Clinical Oncology (2007)

6044 Background: Sorafenib is a potent Raf-1, B-Raf kinase inhibitor and inhibits tyrosine kinases associated with VEGFR-2, 3 and PDGFR-B. We conducted a phase II trial to evaluate the efficacy of BAY 43–9006 in patients with metastatic or recurrent HNSCC. Methods: Chemotherapy naïve patients with histologically proven HNSCC either metastatic, persisted or recurred following definitive treatment, and not amenable to salvage surgical resection were eligible. Patients may have received only one induction or adjuvant chemotherapy regimen provided that at least 6 months elapsed since the last course was administered. Patients must have adequate organ function and a Performance Status of = 1. Sorafenib was administered orally at 400 mg BID on a continuous basis, in 28-day cycles. Responses were evaluated every 8 weeks according to RECIST criteria. The accrual goal was 40 patients. Results: Final accrual was 44 patients. Three patients are ineligible: two with no measurable disease and one with inadequate baseline disease assessment. One eligible patient did not receive any treatment due to noncompliance and is not analyzable. Of the 38 eligible patients assessed for adverse events, there was one Grade 4 toxic event, an asymptomatic pulmonary embolus. Grade 3 toxicities include 3 patients with hand/foot syndrome, 4 with stomatitis, 2 with anorexia and one episode each of esophagitis, dysphagia, xerostomia, hypertension, fatigue, anemia, nausea, hyponatremia and decubitus ulcer. The most common grade 2 toxic events were fatigue, anorexia, stomatitis, and hypertension. Thirty-four eligible patients have been evaluated for response with one confirmed and one unconfirmed partial response. The estimated confirmed response probability is 3% (95% CI: 0 –13%). Two patients remain on treatment. Median follow-up is 9 mos. Median progression-free survival is 4 mos (95% CI: 3 - 4 mos) and median overall survival is 8 mos (95% CI: 7 - 11 mos). In previous SWOG phase II single agent trials in this patient population the median progression-free survival is 2 mos and overall survival is 6 mos. Conclusion: Sorafenib is well tolerated. Although response was poor, PFS and OS compare favorably with previous SWOG phase II single agent trials. No significant financial relationships to disclose.
CANCER AND FROZEN MEAT.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Propylene glycol with occlusion for treatment of ichthyosis
Authors: L. A. Goldsmith
Journal: JAMA (1972)

Rapid clearing of scaling skin in two common skin diseases, X-linked ichthyosis and ichthyosis vulgaris, follows the use of 40% to 60% aqueous solutions of propylene glycol combined with occlusion. Following clearing, intermittent use of this therapy keeps skin free of scales. The therapy can be extended to other skin disorders involving scale accumulation. There are several possible modes of action of this regimen.
CLEQoL 的验证和可靠性
Authors: M.E. Ogunsanya, S.K. Cho, A. Hudson, B.F. Chong
Journal: British Journal of Dermatology (2019)

术语“红斑狼疮”是指一系列相关疾病,而且各种累及皮肤的狼疮统称为皮肤红斑狼疮 (CLE)。CLE 可导致多种不同的皮疹。其中许多通常出现在日晒的身体部位。CLE 患者会出现疲乏、疼痛、瘢痕,甚至日光敏感性,所有这些都会对生活质量 (QoL) 产生不利影响。由于上述症状大部分都很主观,使用适当的量表充分调查患者的 QoL 很重要。因此,美国的这项研究旨在证明皮肤红斑狼疮生活质量(CLEQoL)量表的“信度”和“效度”,这是一个让患者描述CLE对其QoL影响程度的工具。信度是指如果您多次进行同样的检测,您应该每次均获得大致相同的结果,而效度大体上是指该测试检查其预定的项目。研究发现,CLEQoL对评估CLE患者的QoL有充分的信度和效度。我们的结果表明,CLEQoL是一个检查CLE患者QoL的、可行的有用工具,而且可以用于未来药物开发和临床试验,以及在临床实践中用于定期监测患者的健康。
Dermatological Photobiology
Authors: A. Lyell
Journal: BMJ (1976)

This fairly advanced colour atlas of histology continues the tradition of the once famous Atlas and Textbook of Histology and Microscopic Anatomy by Sobotta, and it contains a series of colour-drawings from that work.It comprises 420 illustrations of all the tissues of the body.Most are in colour, the great majority being stained either with haema- toxylin and eosin or with Mallory-azan.
POSTNATAL PERSISTENCE OF RUBELLA VIRUS
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute myeloid leukemia
Authors: Torsten Haferlach
Journal: HemaSphere (2019)

Learning goals To recapitulate state of the art diagnostics as well as treatment strategies in AML and to learn about cutting edge techniques being tested today. To understand that the diagnosis and the treatment of AML is on a fascinating journey from phenotype to genotype, from 3+7 to treatment protocols without standard chemotherapeutic drugs. Introduction We learn to understand the landscape of AML and use this for precision medicine approaches. This does not only include phenotype but also genotype, reflected more and more also in WHO classification (2017) and prognostication systems such as ELN guidelines (2017). It also leads to more understanding in epigenetic features, DNA-damaging and further immune regulation. We further experience a time, when techniques such as Next-generation Sequencing (NGS) are more and more used in routine settings at diagnosis and for follow-up studies such as measurable residual disease (MRD). This is also true for immunophenotyping. However, even new approaches such as mass cytometry are tested in early response evaluation. This all, at diagnosis, for follow-up and at relapse, leads to precision medicine approaches, guided by more specific treatment and - followed complete remission -, individualized therapies guided by MRD.
Summary
Journal: Gut (2002)

of recommendations for colorectal cancer screening and surveillance in high risk groups Disease groups Screening procedure Time of initial screen Screening procedure and interval Annual procedures 300 000 population Colorectal cancer Consultation, LFTs and colonoscopy Colonoscopy within six months of resection only if colon evaluation pre-op incomplete Liver scan within two years post-op Colonoscopy five yearly until 70 years
Risk of congenital dislocated hip.
Journal: BMJ (1967)

Leading Articles BRDICNH 67 were given a second injection of one vial of Triplopen.Further penicillin was given to only five patients, who received another injection of Triplopen on the fifth day.Follow-up of the 82 outpatients was difficult.Many felt so much better that they were reluctant to return to hospital.However, 65 appeared to have done well.Follow-up x-ray examination at the twenty-sixth day showed resolution in 24, and the remainder were not x-rayed but on a medical social worker's follow-up were noted to be well.Five patients could not be traced.The result of treatment was unsatisfactory in 12 patients, in seven of whom resolution was delayed, and in three there was radiographic evidence of pul- monary complications.Two died.There were five deaths among the 18 patients treated in hospital.The higher mor- tality in this group goes some way to justify the criteria used in its selection.No bacteriological data were given in this study, but penicillin-sensitive pneumococci are the organisms found much the most frequently in lobar pneumonia.Sibellas sug- gests that the penicillin regimen might be acceptable for use wherever doctors have to treat lobar pneumonia on an out- patient basis.Conventional methods of treatment of disease may require modification to suit the special needs of communities with shortage of medical facilities.Lobar pneumonia in tropical Africa is only one example of such a situation.More research is needed into the practical prob- lems of treatment in areas where doctors and hospitals are scarce and likely to stay so.
Insomnia
Authors: Sharon Parmet, Alison E. Burke, Richard M. Glass
Journal: JAMA (2006)

Insomnia I nsomnia (trouble falling asleep or staying asleep) is a common problem.It can cause daytime tiredness and sleepiness and difficulty paying attention at school or being alert at work.Insomnia affects people of all ages.Insomnia can be transient (short-term) and related to a specific condition like stress or travel, or it can be a chronic (long-term) problem that persists for many months.The June 28, 2006, issue of JAMA includes an article about treatment of chronic insomnia in older adults.This Patient Page is based on one previously published in the May 21, 2003, issue of JAMA.
Erratum. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care 2021;44:390–398
Authors: Anita Jeyam, Helen Colhoun, Stuart McGurnaghan, Luke Blackbourn, Timothy J. McDonald, Colin N.A. Palmer, John A. McKnight, Mark W.J. Strachan, Alan W. Patrick, John Chalmers, Robert S. Lindsay, John R. Petrie, Sandeep Thekkepat, Andrew Collier, Sandra MacRury, Paul M. McKeigue
Journal: Diabetes Care (2021)
The Fourth Annual Meeting of the Society for Clinical Trials
Journal: JNCI Journal of the National Cancer Institute (1982)

The Fourth Annual Meeting of the Society for Clinical Trials Get access JNCI: Journal of the National Cancer Institute, Volume 69, Issue 4, October 1982, Page 988, https://doi.org/10.1093/jnci/69.4.988 Published: 01 October 1982
Postgraduate course
Journal: Hepatology (2003)

Although family members of incapacitated, critically ill patients often struggle in the role of surrogate decision maker, there are no low-cost, easily-scaled interventions to address this problem.To develop and pilot-test the Family Support Tool, an interactive, web-based tool to help individuals navigate the complexities of surrogate decision making in ICUs.We used a mixed methods, user-centered process to create the Family Support Tool, including: 1) creation of a preliminary design by an expert panel; 2) engagement of a key stakeholder panel to iteratively refine the preliminary design; 3) user testing of a low-fidelity prototype of the tool by 6 former ICU surrogates; 4) creation of a web-based prototype; and 5) user testing of the web-based prototype with 14 surrogates and ICU physicians, including semi-structured interviews and quantitative measurement of usability, acceptability, and perceived effectiveness.The initial design contained a collection of videos and exercises designed to help individuals understand the surrogate's role and think through the patient's values and preferences. Based on family stakeholders' feedback about the emotional overwhelm they experience early in an ICU stay, we redesigned the tool to be viewed in sections, with the first section focused on decreasing surrogates' emotional distress, and later sections focused on helping surrogates prepare for family meetings. Surrogates actively making decisions in the ICU judged the final tool to be highly usable (mean summary score 83.5, correlating to 95th percentile when normalized to devices of its type), acceptable (mean 4.2 +/− 0.5 out of 5), and effective (mean 4.3 +/− 0.6 out of 5). All surrogates reported the tool helped them consider goals of care and all indicated they would recommend the tool to a friend.We successfully developed a web-based tool to help individuals navigate the complexities of surrogate decision making in ICUs that has high potential for scalability. Surrogates judged the tool to be usable, acceptable, and effective. These data support proceeding to test the tool in a pilot randomized clinical trial.
The first step
Authors: J. McDermott
Journal: JAMA (1995)

When we started the health system reform debate, we aspired to a health care system characterized by universality, affordability, security, and choice. Nothing has happened to justify abandoning these health system reform goals. The number of uninsured Americans is increasing, and today almost 40 million of us are without coverage.<sup>1</sup>More employers are dropping insurance, and when people change jobs, their new employers are less likely to provide comparable health benefits.<sup>2,3</sup>In just 5 years, the average health insurance premium for a family will be $9500 per year, not including co-payments and deductibles, assuring that health insurance will be unaffordable to Americans who do not receive coverage through their employment (unpublished data, Congressional Budget Office, 1994). Those Americans who do have insurance are increasingly unable to choose their own physicians and hospitals. Involuntarily forced into managed care plans selected by their employers, more Americans lose their physician every
From the NIH: Collagen provides clues to diagnose spread of cancer to lymph nodes
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Compartmental analysis of steady-state taurocholate transport kinetics by isolated rat hepatocytes
Authors: T Coche
Journal: Hepatology (1991)

We used compartmental modeling to describe taurocholate transport by isolated rat liver cells in suspension. Cells are preincubated in the presence of unlabeled taurocholate. When a steady-state for taurocholate is reached, radiolabeled taurocholate is added to the medium and its exchange kinetics between the medium and the cells are followed over time. Because the studies are performed under steady-state conditions, the kinetics can be described by linear compartmental models. We found a closed two-compartment model sufficient to describe the steady-state transport data. Simulations reveal that if the pools of free and bound intracellular taurocholate exchange rapidly, the cells will behave as a single, kinetically homogeneous compartment and intracellular events will not influence the exchange kinetics of taurocholate between the medium and the cells. The two-compartment model was used to study the concentration dependence of taurocholate transport by isolated cells. Steadystate transport rates and taurocholate concentrations in the medium and the cells were calculated using the model equations. Taurocholate influx, accumulation and efflux processes were studied simultaneously by examining the relationship between appropriate combinations of these variables. Application of this approach to study the inhibition of taurocholate transport by taurochenodeoxycholate is illustrated. In conclusion, this method provides a complementary approach to initial rate studies, which are generally used to investigate bile acid transport by isolated cells. (HEPATOLOGY 1991;13:1203–1214.)
From the NIH: Remote access to professionally reviewed materials provided by AVLINE from National Library of Medicine
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal